- Home
- UMAC vs MNPR Comparison
UMAC vs MNPR Comparison
Compare UMAC & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UMAC
- MNPR
- Stock Information
- Founded
- UMAC 2019
- MNPR 2014
- Country
- UMAC United States
- MNPR United States
- Employees
- UMAC N/A
- MNPR N/A
- Industry
- UMAC
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- UMAC
- MNPR Health Care
- Exchange
- UMAC Nasdaq
- MNPR Nasdaq
- Market Cap
- UMAC 200.1M
- MNPR 209.3M
- IPO Year
- UMAC 2024
- MNPR 2019
- Fundamental
- Price
- UMAC $10.93
- MNPR $44.97
- Analyst Decision
- UMAC Strong Buy
- MNPR Strong Buy
- Analyst Count
- UMAC 2
- MNPR 7
- Target Price
- UMAC $19.00
- MNPR $62.00
- AVG Volume (30 Days)
- UMAC 6.0M
- MNPR 69.2K
- Earning Date
- UMAC 08-13-2025
- MNPR 08-08-2025
- Dividend Yield
- UMAC N/A
- MNPR N/A
- EPS Growth
- UMAC N/A
- MNPR N/A
- EPS
- UMAC N/A
- MNPR N/A
- Revenue
- UMAC $6,988,704.00
- MNPR N/A
- Revenue This Year
- UMAC $160.90
- MNPR N/A
- Revenue Next Year
- UMAC $135.75
- MNPR N/A
- P/E Ratio
- UMAC N/A
- MNPR N/A
- Revenue Growth
- UMAC 1029.19
- MNPR N/A
- 52 Week Low
- UMAC $1.28
- MNPR $1.72
- 52 Week High
- UMAC $23.62
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- UMAC 57.58
- MNPR 59.21
- Support Level
- UMAC $9.61
- MNPR $44.26
- Resistance Level
- UMAC $13.38
- MNPR $47.52
- Average True Range (ATR)
- UMAC 1.37
- MNPR 3.49
- MACD
- UMAC -0.02
- MNPR 0.54
- Stochastic Oscillator
- UMAC 56.78
- MNPR 64.49
About UMAC Unusual Machines Inc. Common Stock
Unusual Machines Inc is engaged in serving the American drone industry by building and selling drone components.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.